Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible staphylococcus aureus osteomyelitis in rabbits

dc.contributor.authorShirtliff, Mark E.
dc.contributor.authorCalhoun, Jason H.
dc.contributor.authorMader, Jon T.
dc.date.accessioned2017-08-21T20:02:47Z
dc.date.available2017-08-21T20:02:47Z
dc.date.issued2001-08
dc.description.abstractMethicillim-susceptible Staphylococcus aureus (MSSA) is the most common pathogen recovered from osteomyelitis patients. The current standard therapeutic method for acute phase osteomyelitis is parenteral anitbiotic therapy. However, parental administration has negative aspects, such as secondary infection, patient inconvenience and high cost. The use of single oral antibiotic therapy may alleviate these problems. Therefore, the purpose of this study was to compare the effectiveness of standard once per day dosing of oral levofloxcin with a standard parenteral antibiotic regimen (nafcillin four times daily) for the treatment of experimental MSSA osteomyelitis in rabbits. Nearly all tibias from untreated infected controls (n = 27) revealed positive cultures (93%) for S. aureus, while the levofloxacin-treated group (n = 20) demonstrated significantly lower percentages of S. aureus infection (50%). The infected tibias of the nafcillin-treated group (n = 20) demonstrated significantly lower percentages (10%) of infected tibias than wither the controls or the levoflaxcin-treated groups (p < 0.05). The inferior efficacy of levoflaxcin may have been due to the pharmacokinetic profile of this fluorouinolone. The serum kinetics demonstrated that following single dose administration, levofloxacin was almost undetectable after 12 h. Studies in which levofloxacin is dosed every 12 h or given at increased doses in order to obtain bactericidal concentrations throughout the treatment regimen are needed.en_US
dc.identifier.citationShirtliff, M.E., J.H. Calhoun, and J.T. Mader, "Comparative Evaluation of Oral Levofloxacin and Parenteral Nafcillin in the Treatment of Experimental Methicillin-Susceptible Staphylococcus aureus Osteomyelitis in Rabbits," J Antimicrob. Chemother., 48:2 (2002).en_US
dc.identifier.issn0305-7453
dc.identifier.urihttps://scholarworks.montana.edu/handle/1/13559
dc.titleComparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible staphylococcus aureus osteomyelitis in rabbitsen_US
dc.typeArticleen_US
mus.citation.extentfirstpage253en_US
mus.citation.extentlastpage258en_US
mus.citation.issue2en_US
mus.citation.journaltitleJournal of Antimicrobial Chemotherapyen_US
mus.citation.volume48en_US
mus.data.thumbpage4en_US
mus.identifier.categoryEngineering & Computer Scienceen_US
mus.identifier.doi10.1093/jac/48.2.253en_US
mus.relation.collegeCollege of Engineeringen_US
mus.relation.departmentCenter for Biofilm Engineering.en_US
mus.relation.departmentChemical & Biological Engineering.en_US
mus.relation.departmentChemical Engineering.en_US
mus.relation.researchgroupCenter for Biofilm Engineering.en_US
mus.relation.universityMontana State University - Bozemanen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
02-013_Modified_enzyme_activity_.pdf
Size:
126.18 KB
Format:
Adobe Portable Document Format
Description:
Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible staphylococcus aureus osteomyelitis in rabbits (PDF)

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
826 B
Format:
Item-specific license agreed upon to submission
Description:
Copyright (c) 2002-2022, LYRASIS. All rights reserved.